Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy

Soumaya Kouidhi1,2,*, Farhat Ben Ayed3 and Amel Benammar Elgaaied2

1 Laboratory BVBGR, LR11ES31, Higher Institute of Biotechnology of Sidi Thabet (ISBST), Department of Biotechnology, University of Manouba, Sidi Thabet, Tunisia, 2 Laboratory of Genetics, Immunology and Human Pathology, Faculty of Sciences of Tunis, Department of Biology, University Tunis El Manar, Tunis, Tunisia, 3 Association Tunisienne de Lutte contre le Cancer (ATCC), Tunis, Tunisia

Currently, a marked number of clinical trials on cancer treatment have revealed the success of immunomodulatory therapies based on immune checkpoint inhibitors that activate tumor-specific T cells. However, the therapeutic efficacy of cancer immunotherapies is only restricted to a small fraction of patients. A deeper understanding of key mechanisms generating an immunosuppressive tumor microenvironment (TME) remains a major challenge for more effective antitumor immunity. There is a growing evidence that the TME supports inappropriate metabolic reprogramming that dampens T cell function, and therefore impacts the antitumor immune response and tumor progression. Notably, the immunosuppressive TME is characterized by a lack of crucial carbon sources critical for T cell function and increased inhibitory signals. Here, we summarize the basics of intrinsic and extrinsic metabolic remodeling and metabolic checkpoints underlying the competition between cancer and infiltrating immune cells for nutrients and metabolites. Intriguingly, the upregulation of tumor programmed death-L1 and cytotoxic T lymphocyte-associated antigen 4 alters the metabolic programme of T cells and drives their exhaustion. In this context, targeting both tumor and T cell metabolism can beneficially enhance or temper immunity in an inhospitable microenvironment and markedly improve the success of immunotherapies.

Keywords: T-lymphocyte metabolism, tumor cell metabolism, tumor microenvironment, immunotherapy, immune checkpoints, metabolic checkpoints

INTRODUCTION

Over the past decades, huge efforts have focused on refinement of conventional cancer therapeutic strategies of chemotherapy, radiation, surgery, or targeted therapies. Although all these advances have displayed clear improvement of clinical outcomes for many types of cancers (1–3), their therapeutic efficacy remains unsatisfactory. Since the cells and the molecules of the immune system

Abbreviations: 2DG, 2-deoxyglucose; ACT, adoptive cell transfer; AMPK, AMP-activated protein kinase; ATP, adenosine triphosphate; CAR, chimeric-antigen receptor; CTLs, cytolytic T cells; CTLA-4, cytotoxic T-lymphocyte antigen; FAO, fatty acid oxidation; HIF, hypoxia-inducible factor; IDO, indoleamine 2,3-dioxygenase; IFN-γ, interferon-γ; LDH, lactate dehydrogenase; MCT, monocarboxylate transporter; mTOR, mammalian target of rapamycin; OXPHOS, oxidative phosphorylation; PD-1, programmed death-1; PD-L1, programmed death ligand-1; PI3K, phosphatidylinositol-3 kinase; PPP, pentose phosphate pathway; TCA, tricarboxylic acid; Teff, effector T cells; Th, helper T cells; TIL, tumor-infiltrating lymphocytes; TME, Tumor microenvironment; Treg, regulatory T cells.
are a fundamental component of the tumor microenvironment (TME), cancer immunotherapy has emerged as a powerful new therapeutic approach to boost antitumor immune response (4). Collectively, the immunotherapy principle consists in the modulation of the immune cells activity, predominantly T cells, using adoptive cell transfer, chimeric-antigen receptor T-cells, or monoclonal antibodies (mAbs) (5, 6). The “Checkpoint blockade” that utilizes mAbs specific to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cellular death protein 1 pathway (PD-1/PD-L1), is arising as a newer strategy used to fight cancer and one of the most promising immunotherapies (7, 8). Indeed, encouraging results demonstrate unprecedented responses in patients with several types of metastatic tumors that were previously resistant to available treatment options (9–11). While these clinical successes have dramatically harnessed host antitumor immunity and clinical outcomes for patients, there are several limitations for immunotherapy (12). In fact, this approach is confronting a highly immunosuppressive TME and low immunogenicity of cancer cells (13). Moreover, despite the success of immunotherapy, mechanisms that govern antitumor immunity and their relevant biomarkers are still being elucidated. Therefore, the development of new methods to overcome such challenge and to improve the efficacy of this therapy is needed in cancer therapy.

Tumor-infiltrating lymphocytes (TIL) reflect tumor biology and prognostic significance. However, they are challenged with a hostile microenvironment that dampsens their function and produces antitumor effects (14). Nevertheless, in the setting of malignancy, multiple mechanisms of immune suppression may exist that prevent effective antitumor immunity (15, 16). Along with negative immunologic regulators called “immune checkpoints,” TIL function is also negatively impacted by a variety of “metabolic checkpoints” (17). Increasing evidence suggests that the deregulation of energy metabolism plays a pivotal role in the inhibition of the antitumor immune response and thereby in tumor progression and metastasis (18). Under a suppressive microenvironment, TIL operate with a metabolic disadvantage since they are subjected to a lack of crucial carbon sources and increased inhibitory signals (19). This may be mainly due to the competition between T cells and tumor cells with deregulated metabolic activities, for limiting nutrients (20). Rapidly dividing tumor cells exhibit complex and dynamic metabolic reprogramming and highly glycolytic level, a phenomenon called the “Warburg effect” and recognized as one of the hallmarks of cancer (21, 22). Thus, tumor cells impede T cell access to nutrients necessary for their activation and generate high levels of lactate. The resulting nutrient scarceness and metabolic waste products accumulation in the TME lead to TIL metabolic switch that impairs their appropriate proliferation and function (23).

Collectively, the cancer cell energetics dictates the metabolic landscape of the TME. Abnormal metabolic activities of cancer cells lead to intratumoral heterogeneity and immunosuppression that could be responsible for the failure of immunotherapy (24, 25). Therefore, a deeper understanding of the metabolic challenges within the TME and their impacts on metabolic fitness of immune cells might contribute the discovery of novel promising approaches to rewire metabolic fitness of TILs that boost existing immunotherapies.

OVERLAPPING METABOLIC PROFILES OF CANCER CELLS AND T LYMPHOCYTES

Metabolism Impacts T Cell Fate and Activation

T cells fate and activation is closely linked to metabolic reprogramming to acquire effector functions (26). Briefly, Naive CD4+ T cells can differentiate into T helper (Th) subsets or into regulatory T cells (Treg), while CD8+ T cells differentiate into effector cytotoxic T lymphocytes (CTLs). Importantly, each T cell functional subset utilizes a distinct metabolic program (27, 28). Highly proliferative cells increase glucose uptake and undergo upregulated aerobic glycolysis, a critical metabolic pathway for activated T cells (29). In parallel to glucose metabolism, T cell activation also enhances mitochondrial biogenesis and oxidative phosphorylation (OXPHOS) and drives mitochondrial membrane hyperpolarization, amino acid uptake, and glutaminolysis (30). There are several signaling pathways that govern the metabolic reprogramming of activated T cells. The critical checkpoint pathways known to regulate the metabolic switch are mammalian target of rapamycin (mTOR) (31) and adenosine monophosphate-activated protein (AMPK) pathways (32). The phosphoinositide-3-kinase (PI3-kinase)-Akt-mTOR pathway is a central integrator of T cell metabolism to sense and require nutrient availability in order to support high glycolytic rate in proliferating T cells (33). Notably, both activated mTOR complexes mTORC1 and mTORC2 play a role in driving glycolysis (34). Additionally, glycolysis activation is concomitant with the pentose phosphate pathway (PPP) upregulation, necessary to build-up of biochemical intermediates that are necessary for nucleotide, amino acid and fatty acid synthesis. Hypoxia-inducible factor-1α (HIF1α) is a master transcription factor enhanced by mTORC activity, which is monitoring and promoting glycolytic enzymes expression (35).

Also, in response to metabolic stress, AMPK inhibits mTOR signaling and increases catabolic metabolism (36). This results in glycolysis suppression and upregulation of oxidative metabolism and mitochondrial complex I activity. AMPK activation promotes generation of Treg, Th1, and Th17 subsets (37).

Metabolism Impacts Tumor Proliferation and Progression

Cancer progression has been recognized for a long time as consequence of multiple genetic events that imply activation of oncogenes and function loss of specific tumor suppressor genes (38, 39). Increasing data point out that this is directly linked to an altered tumor metabolism. Cancer cells exhibit increased glycolysis despite the presence of oxygen, because they must divide rapidly to ensure malignant transformation and tumor development (40, 41). This phenomenon of metabolic reprogramming called “the Warburg effect,” has been recognized as one of the 10 hallmarks of cancer (42). The rate of glycolysis is largely faster than OXPHOS, providing competitive advantages to cancer cells to consume more glucose than surrounding slow-dividing cells and to grow under hypoxia and nutrient deprivation conditions over the TME (43, 44).
Furthermore, glycolysis is an effective metabolic pathway for highly proliferative cancer cells to supply nucleotide, lipid, and amino acid synthesis (45). For instance, increased levels of the glycolysis intermediates provide essential precursors for pivotal anabolic pathways such as the PPP and the serine pathway (46).

It is well established that hypoxia is as a key process supporting glycolysis in tumorigenesis (47). HIF-1α, a transcription factor induced by hypoxia, induces glucose transport by increasing expression of glucose transporters 1–3 along with the transcription of pyruvate dehydrogenase kinase (48). As a result, the tricarboxylic acid cycle is inhibited and several glycolytic enzymes activities are enhanced, including hexokinase 2 (HK2) (49) and lactate dehydrogenase A that converts pyruvate to lactate (50, 51). Therefore, intensive aerobic glycolysis generates high rate of lactate. For instance, the accumulation of lactate in TME results in acidic pH that promotes tumor progression and metastasis and contributes to cancer therapy resistance (52).

While aerobic glycolysis is considered as a key feature in cancer metabolism, clear evidence suggest that mitochondrial metabolism remains functional in most glycolytic cancer cells. Although most cancer cells rely on aerobic glycolysis, it is clear that a tumor displays considerable heterogeneity in metabolic phenotypes (53). Such intratumorally metabolic heterogeneity may be critical for the failure of therapeutic effects. In fact, recent data has shown that cancer stem-like cells (CSCs) exhibit a distinct metabolism from the rest of tumor cells (54). This CSC metabolism depends on mitochondria function (55, 56). Moreover, the particular metabolic phenotype of CSCs may probably render them resistant to conventional antitumor therapies and explain minimal residual disease (57). Interestingly, encouraging results showed that targeting CSC metabolism (by inhibiting mitochondrial biogenesis) could be an attractive approach to reduce drug resistance (58, 59).

**T CELL IMPAIRED FUNCTION UNDER HOSTILE TME**

**Metabolic Interplay between Cancer Cells and TIL in TME**

The tumor tissue consists of complex sets of cell populations including tumor cells, endothelial cells, T cells, natural killer (NK) cells, macrophages, dendritic cells, fibroblasts, and adipocytes. Regarding its genetic and metabolic diversity, this intricate network of cells contributes to the intratumoral heterogeneity. Tumors exhibit a metabolic shift and shape the TME in such a way to support cancer proliferation and metastasis (17, 60). Yet, this milieu is very hostile for T cells to mediate their antitumor effects because of hypoxia, reduced pH and acidosis, inhibitory signals, competition for nutrients, and waste products accumulation (61, 62).

It is well known that tumor cells like effector T cells (Teff), exhibit intensive aerobic glycolysis that improve their metabolic fitness and provide cell-extrinsic advantage, resulting in competition for vital metabolites such as glucose and amino acids. Therefore, tumor-infiltrating T cells are exposed to nutrient depletion in TME and become dysfunctional (62, 63). Nutrient competition has emerged as one of the major axis of tumor immunosuppression due to the anergy and exhaustion of TILs. Indeed, resources scarceness alters T cell activation and antitumor effector functions tumors through several ways (64). Rapidly dividing tumor cells impede T cell access to glucose essential for T cell metabolic switch and activation. Therefore, glucose depletion enhances AMPK pathways and decreases mTORC1 activity, glycolytic capacity, interferon-γ (IFN-γ) production, and cytolytic activity of T cells (65). This may favor Treg subsets instead of Teff and promote tumor progression. Furthermore, decreased levels of amino acids critical for efficient T cell activation and proliferative responses, can modulate the activity of TILs. Glutamine, arginine, and tryptophan deficiency in TME is immunosuppressive and dampens the proliferation of Teff subset (66).

Moreover, it has been recognized that in addition to consumption of key nutrients, tumors produce large amounts of waste products: lactate, arginine and tryptophan by-products, and phosphoenolpyruvate, that impair T cell metabolism and function and confer worse prognosis for patients (67, 68).

Lactate accumulation due to the use of aerobic glycolysis by cancer cells has been described in TME, accompanied by consequent low pH and acidification of the milieu. In mouse models, lactate levels negatively correlate with markers of T cell activation in melanoma (69). The tumor-derived lactate has positive effects on promoting survival, migration and invasion of cancer cells (70). However, lactate negatively impacts T-cell proliferation and function (71). Such acidic condition increases the expression of proangiogenic factors IL-8 and VEGF, both important involved in cancer metastasis (72). Yet, lactate inhibits the phosphatidylino-sitol-3 kinase (PI3K)/Akt/mTOR pathway and thus glycolytic metabolism in T cells by abolishing their cytokine production (73). Lactate also impairs the migration of T cells by reducing the chemokine receptors expression. Added to that, lactate has been demonstrated to be preferentially utilized by Tregs since they prefer oxidative metabolism, resulting in T-cell polarization toward a Treg phenotype. Excess of lactate may also regulate macrophage polarization and represses NK cells functions through a restriction of IFN-γ, IL-10, and TGF-beta (74, 75). Hence, the acidic TME has been contemplated as an attractive target for cancer therapy. Interesting results showed that buffering the tumor pH with bicarbonate improved immunotherapies outcomes.

Proliferative cancer cells create a state of tryptophan deprivation in the TME because of their increased demand for tryptophan (76). Indoleamine 2,3-dioxygenase (IDO) is a pivotal enzyme involved in tryptophan catabolism. IDO is also the first enzyme involved in the production of nicotinamide adenine nucleotide. Uregulation of IDO has been demonstrated to be correlated with an increased malignancy (77). In such context, cancer cells express high levels of IDO that deplete tryptophan availability in the TME and consequently impede T cell responses. In addition to its role in cancer cells, expression of IDO has been shown in other cells: endothelial, tumor-associated macrophages, and dendritic cells and was associated with suppression of antitumor Teff response. IDO contributes to tryptophan deprivation and degradation to kynurenine (78). Accumulation of kynurenine in TME has been described in several tumors leading to immunosuppression (79). Moreover, kynurenine is endogenously able to promote Treg cells and to reduce proliferation of Teff (40). Currently, several trials
targeting IDO in combination with checkpoint inhibition are under investigation (80).

**Crosstalk between Immunologic Checkpoints and T Cell Metabolism**

Immune checkpoint regulators are critical to coordinate effective and efficient immune response, to maintain self-tolerance and to prevent the onset of autoimmunity (81). Nevertheless, T cell effector function is correlated with the expression patterns of coinhibitory and costimulatory immune checkpoint receptors (82). The most described checkpoint proteins playing a central role in maintain immune self-tolerance belong to the TNFR superfamily (83) and B7 family (84).

Tumors can evade immune surveillance through defective immune-checkpoint signaling pathways (81, 85). It is now clear that under tumoral context, aberrantly expressed inhibitory checkpoint proteins are described to disrupt antitumor immune response. CTLA-4 and PD1 are critical coinhibitory receptors highly expressed in T cells under TME (86). Moreover, PD-1 ligands PD-L1 and PD-L2 are upregulated by cancer cells and thus disrupt T cells mediated antitumor response (87). Accordingly, immune checkpoints ligand–receptor interactions were proven to be effective targets to enhance antitumor immunity moving immunotherapy into a new era (88). In fact, immune checkpoints blocking antibodies have achieved an outstanding benefit in cancer treatment enabling patients to produce an effective and durable antitumor response. Currently, three checkpoint inhibitors are approved for the treatment of advanced malignancies: ipilimumab, a CTLA-4-specific mAb (89), and pembrolizumab and nivolumab, which are PD-1-specific mAbs (11). Furthermore, remarkable clinical effectiveness has been reported in other cancers such as, ovarian (90) non–small cell lung carcinoma (91), breast (92), prostate (93), and lymphoma (94).

Although the effectiveness of the immune checkpoint blockade in enhancing antitumor immunity by reducing the number and/or the suppressive activity of Tregs and by restoring the activity of Teff has been reported, little is known about mechanisms underlying T-cell activation. Recent evidence suggest that both checkpoint ligation and inhibition may directly modify metabolism of T cells and cancer cells and alter their metabolic feature. Emerging data have shown that PD-1 binding to its ligands impairs the metabolic phenotype of TIL, by inhibiting glycolysis and upregulating fatty acid oxidation (FAO) (95, 96). CTLA-4 ligation to B7 inhibits glycolysis without augmenting FAO, which suggests that CTLA-4 would not affect the metabolic profile of non-stimulated cells (95). Hence, this abrogation of energy generation impacts antitumor response and leads to reduced cytokine secretion and Teff exhaustion (97). Moreover, immune checkpoints also have an impact on cancer cell metabolic reprogramming. Ligation of PD-L1 directly upregulate glycolysis in cancer cells by promoting glucose uptake and production of lactate (98). Hence, signaling through PD-L1benefits cancer cell metabolism, leading to their expansion and survival (61).

Interestingly, the immune checkpoint blockade appears to differentially impact the metabolic profile in TME by favoring T cell activation and in contrast inhibiting cancer cells. Blocking PD-1 and PD-L1 may reduce glycolysis level in cancer cells by inhibiting mTOR pathway (61). Consequently cancer glucose uptake and lactate secretion decrease which restore glucose availability in TME. Besides, the immune checkpoint blockade has a benefit on T cell metabolism and function. A melanoma mice model study showed that tumor treatment with immune checkpoint inhibitors increases glucose rates in TME and enhances T-cell glycolysis and cytotoxic function (99).

In conclusion, clear evidences demonstrated that tumor cell metabolism deeply affects TME differentiation and functions. By modulating tumor cell metabolism, one can control nutrient availability for T cells, thus promoting either their antitumor or immunosuppressive functions.

**TARGETING METABOLISM FOR EFFICIENT IMMUNOTHERAPY**

**Targeting Glucose Metabolism**

In tumors, T cell activation and proliferation could be impaired by metabolic disruption, therefore cell metabolism becomes an attractive target to restore anti tumor immunity and to develop anticancer therapy (100). However, in tumoral context, it is wise to consider the overlapping metabolic requirements of tumor and immune cells.

Several drugs have been proposed to target tumor glucose metabolism for cancer treatment. For instance, inhibition of glycolytic enzymes that catalyze several steps of glucose metabolism has been known to support anticancer effects (101). 2-Deoxyglucose (2DG) is a non-metabolizable glucose analog and inhibitor of HK used to shut down glycolysis since the first steps. Despite the safety of this drug in cancer patients and its efficiency beyond glycolysis inhibition in cancer cells (102–104), 2DG has also been shown to impair the metabolism of T cells, which results in decreased secretion of cytokines and reduced T cell antitumor function that may be critical for therapeutic success (105). Dichloroacetate (DCA) is another drug targeting cancer cell metabolism which showed conflicting results. DCA is a metabolic disruptor inducing a shift from glycolysis to OXPHOS and inhibiting growth of tumor cells in vitro (106, 107) and in mouse models (108). Similar to 2DG, DCA is not specific to tumor cell metabolism, therefore, it mediates the same metabolic shift in T cells, favoring Treg formation (109).

The TME is particularly immunosuppressive because of lactic acid production in the extracellular milieu that may stand against the therapeutic efficacy (110). To overcome the “Warburg effect” in cancer cells, some therapeutic approaches target lactate with lactate dehydrogenase (LDH) and monocarboxylate transporter (MCT) inhibitors or oral bicarbonate supplementation to tamper the acidic microenvironment (111). Importantly, the inhibition of LDH, the enzyme that catalyzes the conversion of pyruvate into lactate, shows impaired glycolysis and growth arrest in cancer cells (51, 112). Moreover, lactate blockade improves the response to 5-fluorouracil treatment in colorectal cancer (113). However, LDH inhibition demonstrates contradictory results in proliferating T cells response. While it has been reported that deletion of LDH using small-molecule FX11 or Galolflavin ameliorates lactate levels (114, 115), other studies demonstrate that such inhibition leads to a decrease in T cells IFN-γ production (116). Therefore,
the differential impact of LDH inhibitors on cancer and immune cells should be considered when administrated for tumor therapy.

Besides the inhibition of the enzyme LDH, the lactate transporters MCT-1-4 may also be targeted to avoid acidic milieu (117). MCT of the SLC16A gene family influences substrate availability, the metabolic path of lactate and pH balance within the tumor (118). Recent studies have described new MCT disruptors, thalidomide, lenalidomide, and pomalidomide that act on cancer cells to impair the CD147–MCT-1 ligation (119, 120). In addition, the treatment with lenalidomide has been reported to enhance IL-2 and IFN-γ secretion in T cells (121), suggesting that lenalidomide could suppress tumor cell proliferation while favoring T cells activation. Although these drugs cause a loss of cell surface expression of MCT-1, the efficacy may be limited as cancer cells express not only MCT-1 but also MCT-4. Further, AZD3965 another lactate transporter inhibitor, is currently in phase I clinical trials for advanced solid tumors and diffuse large B cell lymphomas (http://www.clinicaltrials.gov:8080/ct2/show/NCT01791595). AZD3965 is targeting MCT-1/MCT-2. Yet, the inhibitory effect has also been observed in T cells (122). Recently, the effect of diclofenac, a non-steroidal anti-inflammatory drug, has been investigated on lactate transport and secretion. Diclofenac has been reported to reduce tumor growth, the number of infiltrating Tregs and the lactate rate in the microenvironment in glioma model (123, 124). Therefore, this result raises the possibility that the application of diclofenac should be feasible to improve the efficacy of immunotherapies.

Further, lactic acid production and resulting low-pH TME are shown to dampen CTLs proliferation and cytotoxic response (125–127). Hence, neutralization of TME may have a meaningful impact on improving the efficacy and outcomes of anticancer immunotherapy therapeutics (128). Emerging data show that buffering lactic acid with bicarbonate or proton pump inhibitor, Esomeprazole improves the pH of TME (129, 130). More importantly, neutralization of TME pH improves outcomes in CTLs and in NK cell mediated anticancer as well. Notably, buffering TME with oral bicarbonate inhibits tumor growth when combined with anti-PD-1 immunotherapy in a melanoma model, and improves survival when combined with adoptive T-cell transfer (131). Altogether, these data indicate that targeting TME acidification by buffering provide a new perspective for immunotherapy outcomes.

The PI3K-AKT-mTOR is an important pathway well known to play a critical role in cancer and immune cell metabolism (31, 132). Further, this pathway has been extensively studied in various cancers showing inappropriate activation supporting tumor growth and survival. Over the last decades, several therapies were developed against mTOR signaling in several solid malignancies (133, 134). Analogs of rapamycin, a drug that inhibits the mTOR signaling, have been approved for the treatment of breast (135), renal (136), and pancreatic cancers (137). An increasing number of studies have reported that inhibition of the mTOR pathway suppresses the glycolytic metabolism and sensitizes tumor cells to chemotherapy (138, 139). Yet, it has been reported that rapamycin can mediate opposite effects on T cells since it broadens Tregs and cytotoxic memory T cells but at the same time decreases Teff proliferation (140). Interestingly, recent evidence suggest that treatment with rapamycin combined with immunotherapy augments cytotoxic and memory T-cell functions in glioblastoma cancer (141). Therefore, rapamycin could be an attractive adjuvant to be used in combination with immunotherapy.

Besides glycolysis, OXPHOS is also a possible target structure in cancer cells. Several reports have described the potential effects of metformin, which is commonly used to treat type II diabetes, as an anticancer drug. Indeed, a large number of retrospective clinical studies and randomized control trials show that metformin prevents tumor growth and improves clinical prognosis in various cancers including lung and prostate cancers (142, 143).

Interestingly, those effects seem to be partially immunemediated as metformin improved T cell function in vivo (144). Further, metformin has been proposed as a treatment for melanomas due to the limitations of current therapies (145). Metformin is known to target the mitochondrial respiratory complex I and to activate AMPK pathway signal transduction (146, 147). Several reports have demonstrated that AMPK plays pleiotropic and conflicting effects at the interface of cellular metabolism and function (37). In fact, activated AMPK may engender both antitumor and protumor effects in a manner not yet understood (148, 149). Notably, activated AMPK pathway impedes mTOR signaling, and shuts down glycolytic gene expression leading to antiproliferative effects in cancer (150, 151). However, AMPK activation on another side helps cancer cells accommodation to metabolic stresses, which raises their survival (152). Metformin’s AMPK activating effects could also impact T cells behavior mainly by enhancing memory T cells (105, 153) and Treg expansion (154). Therefore, metformin treatment may improve secondary responses. Yet it could favor immunosuppressive Treg cells in TME.

### Targeting Amino Acid Catabolism

In the context of the TME, cancer cells require a continuous and high rate of supply of energy to take advantage of their metabolic reprogramming and to avoid immune surveillance. In fact, cancer cells create a state of nutrient deprivation for the T cells and redirect glucose and amino acids for their own advantage. It is well known that L-arginine, tryptophan and glutamine are fundamental in tumor progression and immunity (155). Therefore, targeting these amino acids in cancer therapy becomes a promising strategy for the development of novel therapeutic agents (156). In fact, many clinical trials are actually testing specific drugs inhibiting amino acid metabolism in cancer cells. Depletion of arginine was assessed using ADI-PEG20 inhibitor (157). It can inhibit cell proliferation in vitro and tumor growth in vivo and decrease Treg accumulation (158). However, it would be more pertinent to prevent amino acid depletion by tumor cells or myeloid cells rather than decreasing amino acid rates in the TME. This approach is currently tested in a clinical trial with CB-1158, an ARG inhibitor, in combination with checkpoint therapy (159).

Furthermore, increasing evidence suggest that tryptophan is critical in supporting oncogenic signature and in maintaining the immunosuppressive phenotype in several cancers (160). Interestingly, it has been reported that the silencing of IDO boosted antitumor immunity in metastatic liver tumor model (161), improved cytotoxic T cell function and decreased Treg numbers (162). Accordingly, it is well established that IDO is a key target of drug discovery in cancer immunotherapy (80, 163). Imatinib is another drug displaying improved anti tumor...
immunity by activating T effector cells and suppressing Tregs, in a manner dependent on IDO pathway (164). For instance, a current clinical trial is assessing the combination between imatinib and anti-CTLA4 approach in GIST (165).

Glutamine is considered as a critical amino acid for cancer cell metabolism as well as for rapidly dividing T cells. To overcome the high glutamine consumption rates of cancer cells, several therapeutic agents targeting glutamine metabolism have been explored in preclinical studies (166). Three compounds were assessed as glutamine analogs, 6-diazo-5-oxo-L-norleucine, azaserine, and acivicin. These agents showed impaired activity of enzymes utilizing glutamine in many tumor models (167, 168). Moreover, testing glutamine transporter inhibitors gamma-l-glutamyl-p-nitroanilide and benzylserine [H-Ser(Bzl)-OH], showed reduced glutamine uptake and cell growth in lung and prostate cancers (169, 170). Yet, glutamine plays also a key role in normal Teff. Therefore, it is conceivable to consider better tumor-targeting options under the TME.

CONCLUDING REMARKS

Cancer immunotherapy provides successful and powerful opportunity in cancer treatment. However, it is important to get comprehensive understanding of mechanisms leading to reduced antitumor immunity under hostile TME. Importantly, TILs have to surpass not only immune checkpoints but also a wide range of metabolic checkpoints that fate their energetic behavior defects and dampen their function. In fact, cancer cells upregulate nutrients uptake and waste metabolites production to generate an immunosuppressive TME that allows their evasion and growth, and that dictates immune cell fate (Figure 1A). Increasing emerging data point out the modulation of cellular metabolism, using combinational approaches of metabolic disruptors with immune checkpoint blockade (Figure 1B). However, a special attention should be devoted to target specific tumor site, in order to avoid systemic toxicity and innumerable other side effects. In summary, by operating through distinct and complementary mechanisms, these new therapeutic strategies might reinvigorate TILs by restoring their metabolic properties and improving the efficacy of immunotherapies.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
REFERENCES

1. Palumbo MO, Kavan P, Miller WH, Panasci L, Assouline S, Johnson N, et al. Systemic cancer therapy: achievements and challenges that lie ahead. Front Pharmacol (2013) 4:57. doi:10.3389/fphar.2013.00057

2. Chabner BA, Roberts TC. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer (2005) 5(1):65–72. doi:10.1038/nrc1529

3. DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res (2008) 68(21):8643–53. doi:10.1158/0008-5472.CAN-07-6611

4. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer (2011) 11(1):805–12. doi:10.1038/nrc3153

5. Papaioannou NE, Beniati OV, Vitsos P, Tisitisionis O, Samara P. Harnessing the immune system to improve cancer therapy. Ann Transl Med (2016) 4(14):261. doi:10.21037/amt.2016.04.01

6. Rosenberg SA, Yang JC, Sherry RM, Kamnula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 17(13):4550–7. doi:10.1158/1078-0432.CCR-11-0116

7. Zavala VA, Kalergis AM. New clinical advances in immunotherapy for the treatment of solid tumours. Immunology (2015) 145(2):182–201. doi:10.1111/imn.12459

8. Schwab CL, English DP, Roque DM, Pasternak M, Santin AD. Past, present and future targets for immunotherapy in ovarian cancer. Immunotherapy (2014) 6(12):1279–93. doi:10.2217/imt.14.19

9. Hwang SJE, Fernández-Peñas P. Adverse reactions to biologics: melanoma and future targets for immunotherapy. Clin Ther (2014) 36(12):1279–93. doi:10.2217/imt.14.90

10. Lee JH, Lyle M, Menzies AM, Chan MM, Lo S, Clements A, et al. Metastasis-inhibitors: PD-1/PD-L1 blockade in melanoma. Immunotherapy (2017) 8(1):19–34. doi:10.21037/imi.2017.02.018

11. Routy J-P, Routy B, Graziani GM, Yokozeki Y. The kynurenine pathway is a new checkpoint for anti-tumor immunity. Cancer Metab (2015) 3:1. doi:10.3389/fimmu.2015.00001

12. Waickman AT, Powell JD, mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunol Rev (2012) 249(1):43–58. doi:10.1111/j.1600-6565.2012.01152.x

13. Ma EH, Poffenberger MC, Wong AH-T, Jones RG. The role of AMPK in T cell metabolism and function. Curr Opin Immunol (2017) 46:45–52. doi:10.1016/j.coi.2016.07.004

14. Zeng H, Cohen S, Guy C, Shrestha S, Neale G, Brown SA, et al. mTORC1 and mTORC2 kinase signaling and glucose metabolism drive follicular T cell differentiation. Immunity (2016) 45(3):540–54. doi:10.1016/j.immuni.2016.08.017

15. Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in vivo. Immunity (2015) 42(1):41–54. doi:10.1016/j.immuni.2014.12.030

16. Gluskin EM, Shaw RJ. AMPK control of mTOR signaling and growth. (2010) 249(1):43–58. doi:10.3389/fimmu.2015.00001

17. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 403(6769):503–11. doi:10.1038/35008000

18. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 403(6769):503–11. doi:10.1038/35008000

19. Wang R, Green DR. Metabolic checkpoints in activated T cells. Nat Immunol (2012) 13(10):907. doi:10.1038/ni.2386

20. Elgaaied AB, Chouaib S. Impact of metabolism on T cell differentiation, and functions. Front Immunol (2015) 6:1. doi:10.3389/fimmu.2015.00001

21. Araujo L, Khim P, Mikhikian H, Mortales C-L, Demetriou M. Glycolysis and glutaminolysis cooperatively control T-cell function by limiting metabolic supply to N-glycosylation. eLife (2017). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5257576/

22. Ley L, Relman DA. The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity (2015) 42(1):41–54. doi:10.1016/j.immuni.2014.12.030

23. Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in vivo. Immunity (2015) 42(1):41–54. doi:10.1016/j.immuni.2014.12.030

24. Gluskin EM, Shaw RJ. AMPK control of mTOR signaling and growth. (2010) 249(1):43–58. doi:10.3389/fimmu.2015.00001

25. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 403(6769):503–11. doi:10.1038/35008000

26. Wang R, Green DR. Metabolic checkpoints in activated T cells. Nat Immunol (2012) 13(10):907. doi:10.1038/ni.2386

27. Delgoffe GM, Powell JD. Feeding an army: the metabolism of T cells in activation, anergy, and exhaustion. Mol Immunol (2015) 68(2 Pt 1):492–6. doi:10.1016/j.molimm.2015.07.026

28. Motz GT, Coukos G, Kroemer G, Hess C. The spectrum of T cell metabolism in health and disease. Nat Rev Immunol (2017) 17(1):19–34. doi:10.1038/nri.2017.99

29. Palmer CS, Ostrowski M, Balderson B, Christow N, Crowe SM. Glucose metabolism regulates T cell activation, differentiation, and functions. Front Immunol (2015) 6:1. doi:10.3389/fimmu.2015.00001

30. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 403(6769):503–11. doi:10.1038/35008000

31. Wang R, Green DR. Metabolic checkpoints in activated T cells. Nat Immunol (2012) 13(10):907. doi:10.1038/ni.2386

32. Delgoffe GM, Powell JD. Feeding an army: the metabolism of T cells in activation, anergy, and exhaustion. Mol Immunol (2015) 68(2 Pt 1):492–6. doi:10.1016/j.molimm.2015.07.026

33. Balaghi J, Coulombe F, Vincent EE, Dupuy F, Galicia-Vázquez G, Yurchenko E, et al. The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity (2015) 42(1):41–54. doi:10.1016/j.immuni.2014.12.030

34. Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in vivo. Nat Rev Cancer (2008) 8(11):851. doi:10.1038/nrc2501

35. Gluskin EM, Shaw RJ. AMPK control of mTOR signaling and growth. (2010) 249(1):43–58. doi:10.3389/fimmu.2015.00001

36. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 403(6769):503–11. doi:10.1038/35008000

37. Wang R, Green DR. Metabolic checkpoints in activated T cells. Nat Immunol (2012) 13(10):907. doi:10.1038/ni.2386

38. Delgoffe GM, Powell JD. Feeding an army: the metabolism of T cells in activation, anergy, and exhaustion. Mol Immunol (2015) 68(2 Pt 1):492–6. doi:10.1016/j.molimm.2015.07.026
Delgoffe GM. Filling the tank: keeping antitumor T cells metabolically fit for the long haul.

Chang C-H, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Hallmarks of cancer stem cell metabolism: a potential target for cancer therapy. 

Alvarez R, et al. Mitochondrial biogenesis is required for the anchorage-dependent survival and propagation of stem-like cancer cells.

Zhao H, Jiang H, Li Z, Zhuang Y, Liu Y, Zhou S, et al. 2-Methoxyestradiol enhances radiosensitivity in radioresistant melanoma MDA-MB-435 cells by regulating glycolysis via HIF-1α/PI3K/AKT axis. Int J Oncol (2017) 50(3):1531–40. doi:10.3892/ijo.2017.3924

Gao C, Yan X, Wang B, Yu L, Han J, Li D, et al. Jolkinitolide B induces apoptosis and inhibits tumor growth in mouse melanoma B16F10 cells by altering glycolysis. Sci Rep (2016) 6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5086858/

Wang J, Wang H, Liu A, Fang C, Hao J, Wang Z. Lactate dehydrogenase A negatively regulated by miRNAs promotes aerobic glycolysis and is increased in colorectal cancer. Oncotarget (2015) 6(23):19456–68. doi:10.18632/oncotarget.3318

Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, et al. Inhibitory effect of tumor-cell-derived lactic acid on human T cells. Blood (2011) 117(24):9812–9. doi:10.1182/blood-2006-07-035972

Ruan G-X, Kazlauskaas A. Lactate engages receptor tyrosine kinases Axl, Tie2, and vascular endothelial growth factor receptor 2 to activate phosphoinositide 3-kinase/Akt and promote angiogenesis. J Biol Chem (2013) 288(29):21161–72. doi:10.1074/jbc.M113.474619

Chen JL-Y, Lucas JE, Schroeder T, Mori S, Wu J, Nevinjs J, et al. The genomic analysis of lactate acidosis and acidosis response in human cancers. PLoS Genet (2008) 4(12):e1000293. doi:10.1371/journal.pgen.1000293

Scott KEN, Cleveland JL. Lactate wreaks havoc on tumor-infiltrating T and NK cells. Cell Metab (2016) 24(5):649–50. doi:10.1016/j.cmet.2016.10.015

Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab (2016) 24(5):657–71. doi:10.1016/j.cmet.2016.08.011

Timosenko E, Ghabbane H, Silk JD, Shepherd D, Gileadi U, Howson LJ, et al. Nutritional stress induced by tryptophan-degrading enzymes results in ATF4-dependent reprogramming of the amino acid transporter profile in tumors. Cancer Res (2017) 76(21):6193–204. doi:10.1158/0008-5472.CAN-15-3502

Silk JD, Lakhil S, Laynes R, Vallius L, Karydis I, Marcea C, et al.IDO induces expression of a novel tryptophan transporter in mouse melanoma B16F10 cells.

Platten M, Wick W, Van den Eynde BJ. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res (2012) 72(21):5435–40. doi:10.1158/0008-5472.CAN-12-0569

Katz JB, Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunity Rev (2005) 6(6):223. doi:10.1186/gb-2005-6-6-223

Lim S, Phillips JR, da Silva LM, Zhou M, Fodstad O, Owen LB, et al. Interplay between immune checkpoint proteins and cellular metabolism. Cancer Res (2017) 77(6):1245–9. doi:10.1158/0008-5472.CAN-16-1647

Cox N, Towbin GJ, Wargo JA. Hallmarks of response to immune checkpoint receptor blockade. Br J Cancer (2017) 117(1):1–7. doi:10.1038/bjc.2017.136

Rackley RM, Kileen N, Lenardo MJ, The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell (2001) 104(4):487–501. doi:10.1016/S0092-8674(01)00237-9

Collins M, Ling V, Carrreno BM. The B7 family of immune-regulatory ligands. Genome Biol (2005) 6(6):223. doi:10.1186/gb-2005-6-6-223

Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res (2015) 21(4):687–92. doi:10.1158/1078-0432.CCR-14-1860
86. Dong T, Sun Q, Zhang X. PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget (2016) 8(2):2171–86. doi:10.18632/ oncotarget.13888

87. Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother (2005) 54(4):307–14. doi:10.1007/s00262-004-0593-x

88. Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol (2017) 8:561. doi:10.3389/fphar.2017.00561

89. Sachpekitis C, Hassel JC, Dimitrakopoulou-Strauss A. Metastatic melanoma response to combination therapy with ipilimumab and vemurafenib. Hell J Nucl Med (2017) 20(3):251–3. doi:10.1697/2014.25101161

90. Duraiswamy I, Freeman GI, Coukos G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res (2013) 73(23):6900–12. doi:10.1158/0008-5472.CAN-13-1550

91. Ramos-Esquível A, van der Laat A, Rojas-Vigot R, Juárez M, Corrales-Rodríguez L. Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials. ESMO Open (2017) 2(3):e000236. doi:10.1136/esmoopen-2017-000236

92. Li H, Trisciu GI, Wang X, Wang Y, Ren X, Harvey HA, et al. Immunotherapy for triple-negative breast cancer: existing challenges and exciting prospects. Drug Resist Updat (2017) 32:1–15. doi:10.1016/j.drup.2017.07.002

93. Thompson RH, Allison JR, Kwon ED. Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol Oncol (2006) 24(5):442–7. doi:10.1016/j.urolonc.2005.08.011

94. Montico B, Lapenta C, Ravo M, Martorelli D, Muraro E, Zeng B, et al. Metabolic remodeling, signaling and bioenergetic therapy. Cancer Metastasis Rev (2010) 29(5):2037–42. doi:10.1007/s10620-010-9287-3

95. Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell LN, et al. PD-1 alters metabolic remodeling of cancer cells in combination with Bevacizumab. Mol Cancer (2015) 14:1967–91. doi:10.4155/mcc.15.131

96. Doherty JR, Cleveland FL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest (2013) 123(9):3685–6. doi:10.1172/JCI69741

97. Huber V, Camisaschi C, Berzi A, Ferro S, Lugini L, Triulzi T, et al. Cancer acidity: an ultimate frontier of tumor immune escape and a novel target of immunomodulation. Semin Cancer Biol (2017) 43(Suppl C):74–89. doi:10.1016/j.semcancer.2017.03.001

98. Hong C, Graham NA, Gu W, Espindola Camacho C, Mah V, Mares EL, et al. MCT1 modulates cancer cell pyruvate export and growth of tumors that co-express MCT1 and MCT4. Cell Rep (2016) 14(7):1590–601. doi:10.1016/j.celrep.2016.01.057

99. Kennedy KM, Dewhirst MW. Tumor metabolism of lactate: the influence and therapeutic potential of MCT and CD147 regulation. Future Oncol (2010) 6(12):1271–9. doi:10.2217/fon.09.145

100. Pinheiro C, Reis RM, Longatto-Filho A, Schmitt F, Baltazar F. Expression of monocarboxylate transporters 1, 2, and 4 in human tumors and their association with CD147 and CD44. J Biomed Biotechnol (2010). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2863082/

101. Eicher R, Heider M, Fernández-Sáiz V, van Bebber F, Garz A-K, Lemmer S, et al. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. Nat Med (2016) 22(7):735–43. doi:10.1038/nm.4112

102. Görgün G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M, et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood (2010) 116(7):3227–37. doi:10.1182/blood-2010-04-279893

103. Bola BM, Chadwick AL, Michopoulos F, Blount KG, Telfer BA, Williams KJ, et al. Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport. Mol Cancer Ther (2014) 13(12):3005–16. doi:10.1158/1535-7163.MCT-13-1091

104. Chirasani SR, Leukel P, Gottfried E, Hochrein J, Stadler K, Neumann B, et al. Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model. Int J Cancer (2013) 132(4):843–53. doi:10.1002/ijc.27712
Bosticardo M, Ariotti S, Losana G, Bernabei P, Forni G, Novelli F. Biased activation of human T lymphocytes due to low extracellular pH is antagonized by B7/C2D8 costimulation. *Eur J Immunol* (2001) 31(9):2829–38. doi:10.1002/1614-5702(200109)31:9<2829::AID-IMMU2829>3.0.CO;2-U

Romero-García S, Moreno-Altamirano MMP, Prado-García H, Sánchez-García FJ. Lactate contribution to the tumor microenvironment: mechanisms, effects on immune cells and therapeutic relevance. *Front Immunol* (2016) 7:52. doi:10.3389/fimmu.2016.00552

Choi SYC, Collins CC, Gout PW, Wang Y. Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite? *J Pathol* (2013) 230(4):350–5. doi:10.1002/path.4218

Fais S. Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism. *J Intern Med* (2010) 267(5):515–25. doi:10.1111/j.1365-2796.2010.02225.x

Kohli T. Cancer: fundamentals behind pH targeting and the double-edged sword of hypoxia. *Oncotarget* (2016) 7(36):58075–88. doi:10.18632/oncotarget.15524

Pilon-Thomas S, Kodumudi KN, El-Kenawi AE, Russell S, Weber AM, Luddy K, Koltai T. Cancer: fundamentals behind pH targeting and the double-edged sword of hypoxia. *Oncotarget* (2016) 9:6343–60. doi:10.2147/OTT.S115438

Lee S-Y, Lee SH, Yang E-J, Kim E-K, Shin J-K, Shin D-Y, et al. Metformin ameliorates inflammatory bowel disease by suppression of the stat3 signaling pathway and regulation of the between Th17/Treg balance. *PLoS One* (2015) 10(9):e0135858. doi:10.1371/journal.pone.0135858

Luo Z, Zang M, Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. *Future Oncol* (2010) 6(3):457–70. doi:10.2217/fon.09.179

Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. *Cell Metab* (2013) 17(1):113–24. doi:10.1016/j.cmet.2012.12.001

Dandapani M, Hardie DG. AMPK: opposing the metabolic changes in both tumour cells and inflammatory cells? *Biochem Soc Trans* (2013) 41(2):687–93. doi:10.1042/BST20130531

Zhao Y, Hu X, Liu Y, Dong S, Wen Z, He W, et al. ROS signaling under metabolic stress: cross-talk between AMPK and AKT pathway. *Mol Cancer* (2017) 16. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930606/

Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang L-S, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. *Nature* (2009) 460(7251):103–7. doi:10.1038/nature08097

Lee S-Y, Lee SH, Yang E-J, Kim E-K, Shin J-K, Shin D-Y, et al. Metformin ameliorates inflammatory bowel disease by suppression of the stat3 signaling pathway and regulation of the between Th17/Treg balance. *PLoS One* (2015) 10(9):e0135858. doi:10.1371/journal.pone.0135858

Lukey MJ, Katt WP. Ceronie RA. Targeting amino acid metabolism in cancer therapy. *Drug Discov Today* (2017) 22(5):796–804. doi:10.1016/j.drudis.2016.12.003

Ananieva E. Targeting amino acid metabolism in cancer growth and anti-tumor immune response. *World J Biol Chem* (2015) 6(4):281–9. doi:10.4331/wjbc.v6.i4.281

Kremer JC, Prudner BC, Lange SES, Bean GR, Schultz MB, Brashears CB, et al. Arginine deprivation inhibits the warburg effect and upregulates glutamine metabolism and serine biosynthesis in ASS1-deficient cancers. *Cell Rep* (2017) 18(4):991–1004. doi:10.1016/j.celrep.2016.12.077

Brin E, Wu K, Lu H-T, He Y, Dai Z, He WEPGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor cell infiltration. *Oncotarget* (2017) 8(35):58948–63. doi:10.18632/oncotarget.19564

Arginase inhibitor INCB011938 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors. *Clinical Trials* (2017). Available from: https://clinicaltrials.gov/ct2/show/NCT02903914

van Baren N, Van den Eynde BJ. Tryptophan-degrading enzymes in tumoral and molecular mechanisms of metformin: an overview. *Future Oncol* (2010) 6(3):457–70. doi:10.2217/fon.10.94

van Baren N, Van den Eynde BJ. Tryptophan-degrading enzymes in tumoral and molecular mechanisms of metformin: an overview. *Future Oncol* (2010) 6(3):457–70. doi:10.2217/fon.10.94
164. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, et al. Imatinib potentiates anti-tumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. *Nat Med* (2011) 17(9):1094–100. doi:10.1038/nm.2438

165. Reilley MJ, Bailey A, Subbiah V, Janku F, Naing A, Falchook G, et al. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. *J Immunother Cancer* (2017) 5:35. doi:10.1186/s40425-017-0238-1

166. Altman BJ, Stine ZE, Dang CV. From krebs to clinic: glutamine metabolism to cancer therapy. *Nat Rev Cancer* (2016) 16(10):619–34. doi:10.1038/nrc.2016.71

167. Lynch G, Kemeny N, Casper E. Phase II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma. *Am J Clin Oncol* (1982) 5(5):541–3. doi:10.1097/00000421-198210000-00014

168. Ahluwalia GS, Grem JL, Hao Z, Cooney DA. Metabolism and action of amino acid analog anti-cancer agents. *Pharmacol Ther* (1990) 46(2):243–71. doi:10.1016/0163-7258(90)90094-I

169. van der Mijn JC, Panka DJ, Geissler AK, Verheul HM, Mier JW. Novel drugs that target the metabolic reprogramming in renal cell cancer. *Cancer Metab* (2016) 4. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944519/

170. Hassanein M, Qian J, Hoeksema MD, Wang J, Jacobovitz M, Ji X, et al. Targeting SLC1a5-mediated glutamine dependence in non-small cell lung cancer. *Int J Cancer* (2015) 137(7):1587–97. doi:10.1002/ijc.29535

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.